Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism Prophylaxis
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorRon Beloosesky MD
About this trial
The purpose of this study is to compare the use of oral apixaban to subcutaneous enoxaparin for venous thromboembolism (VTE) prophylaxis in postpartum women at high risk for VTE. The primary goal is to evaluate medication adherence rates and patient satisfaction with the treatment.
Eligibility criteria
Qualifiers
Age ≥ 18 years.
After Vaginal or C/S delivery.
Need prophylactic treatment in a preventive dose.
Presence of one or more high risk factors: Active infection, IBD, Heart disease, Type 1 diabetes with nephropathy, IV drug user, Surgical operation in Postpartum period, Emergency cesarean section.
Disqualifiers
Breast feeding.
Predispose to hypercoagulability
Familial history of VTE.
Antiphospholipid syndrome (APS).
Trial design
Treatments tested in this trial
- Apixaban
- Enoxaparin
Treatment groups
150 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Ron Beloosesky MD
Lead sponsor
Rambam Health Care Campus
Sponsor institution
Source ClinicalTrials.gov